NCT03185923 is a Phase 3 clinical trial of TCM plus conventional drug in Community-Acquired Infections, sponsored by Henan University of Traditional Chinese Medicine.

Who is sponsoring NCT03185923?

NCT03185923 is sponsored by Henan University of Traditional Chinese Medicine.

What drugs are being tested in NCT03185923?

Interventions in NCT03185923: TCM plus conventional drug, TCM placebo plus conventional drug.

What condition does NCT03185923 study?

NCT03185923 studies Community-Acquired Infections.

Is NCT03185923 still recruiting?

NCT03185923 is currently status unknown. Last updated 14 June 2017.

Last reviewed 2017-06-14 · How we verify

NCT03185923

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe Pneumonia

Status unknown Phase 3 Last updated 14 June 2017

What this trial tests

Phase 3 trial testing TCM plus conventional drug in Community-Acquired Infections in 198 participants. Status unknown.

Timeline

20 June 2017

Primary endpoint
31 December 2019

31 December 2020

Quick facts

Lead sponsor	Henan University of Traditional Chinese Medicine
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	198
Start date	20 June 2017
Primary completion	31 December 2019
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

TCM plus conventional drug — full drug profile →
TCM placebo plus conventional drug

Conditions studied

Community-Acquired Infections — all drugs for Community-Acquired Infections →

Sponsor

Henan University of Traditional Chinese Medicine

Who can join

Adults 18 to 80, any sex, with Community-Acquired Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the integrated traditional Chinese and Western medicine in the treatment of severe community acquired pneumonia in adults. Half of participants will receive traditional Chinese and Western medicine in combination, while the other half will receive a placebo traditional Chinese and Western medicine.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Integrated traditional Chinese and conventional medicine in treatment of severe community-acquired pneumonia: study protocol for a randomized placebo-controlled trial.
Wang H, Li J, Yu X, Li SY. · · 2018 · cited 7× · PMID 30419961 · DOI 10.1186/s13063-018-3005-9
Traditional Chinese Medicine treatment with syndrome differentiation for patients with severe community-acquired pneumonia: a multicenter, randomized, placebo-controlled trial.
Jiansheng LI, Haifeng W, Kang Z, Kai X, et al · · 2025 · PMID 41376229 · DOI 10.19852/j.cnki.jtcm.2025.06.015

Verify or expand the search:

Other trials of TCM plus conventional drug

Trials testing the same drug.

NCT06714032 — Effect of Traditional Chinese Medicine of Severe COVID-19 · Phase 3 · completed

Other Henan University of Traditional Chinese Medicine trials

Trials by the same sponsor.

NCT07352488 — Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome · NA · not yet recruiting
NCT07206745 — A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bact · NA · not yet recruiting
NCT07178392 — Disease-syndrome Characteristics of IPF · not yet recruiting
NCT07162870 — Idiopathic Pulmonary Fibrosis Cohort of TCM · not yet recruiting
NCT06914713 — Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03185923 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan University of Traditional Chinese Medicine
Last refreshed: 14 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03185923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing